Evidence map›Paper›PMID 37969727›Full record

ReviewActa pharmaceutica Sinica. B2023

Current research trends of nanomedicines.

Qiuyue Liu, Jiahui Zou, Zhongjian Chen, Wei He, Wei Wu

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Global research trends of nanotechnology for pain management.Frontiers in bioengineering and biotechnology · 2023
    Pooled it
  3. Green Synthesis and Characterization of SiOApplied biochemistry and biotechnology · 2026
    Article
  4. A Novel Reporter Mouse for Astrocyte-Derived Extracellular Vesicles Reveals Enrichment of Cargo at Neuronal Mitochondria.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. ZnJournal of nanobiotechnology · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qiuyue LiuShanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
Jiahui ZouSchool of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Zhongjian ChenShanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
Wei HeShanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.
Wei WuShanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Owing to the inherent shortcomings of traditional therapeutic drugs in terms of inadequate therapeutic efficacy and toxicity in clinical treatment, nanomedicine designs have received widespread attention with significantly improved efficacy and reduced non-target side effects. Nanomedicines hold tremendous theranostic potential for treating, monitoring, diagnosing, and controlling various diseases and are attracting an unfathomable amount of input of research resources. Against the backdrop of an exponentially growing number of publications, it is imperative to help the audience get a panorama image of the research activities in the field of nanomedicines. Herein, this review elaborates on the development trends of nanomedicines, emerging nanocarriers,

Indexed as

Clinical translationDrug deliveryIn vivo fateNanocarriersNanomedicineNanoparticlesProtein coronaTrigger-responsive

Identifiers

PMID37969727
PMCPMC10638504

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.